PureTech Health-backed neuropsychiatric drug developer Karuna Therapeutics raised $89.2m in an upsized offering that followed $123m in venture capital.

AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.

Morphic began trading on the Nasdaq Global Market yesterday after issuing 6 million shares priced at $15 each, providing exits to AbbVie, GSK, Novo, Pfizer, Schrödinger and ShangPharma.

Shares in Adaptive Biotechnologies, backed by Microsoft, Celgene, Illumina, LabCorp and BD Biosciences, soared more than 100% on its first day of trading.

Novel Group-backed luxury goods marketplace The RealReal will raise $300m in an initial public offering in which it will float above its range.

Morphic began trading on the Nasdaq Global Market yesterday after issuing 6 million shares priced at $15 each, providing exits to AbbVie, GSK, Novo, Pfizer, Schrödinger and ShangPharma.

Shire and Novo are in line for exits from liver disease startup Mirum Pharmaceuticals, which has filed to raise $86.3m in its IPO.

Ford and Baidu are in line for exits after 3D sensor technology developer Velodyne Lidar appointed banks to underwrite an IPO expected to value it at $1.8bn.

The fast fashion retailer has invite banks to apply for roles in the offering, having raised its first external financing in a Tencent-backed round last year.

The GlaxoSmithKline, Sanofi Ventures and 6 Dimensions Capital-backed genetically-defined disease therapy developer has filed for an $86.3m offering.